Skip to main content
Figure 5 | Journal for ImmunoTherapy of Cancer

Figure 5

From: Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Figure 5

High on-treatment cDC1/cDC3/monocyte activation and low pretreatment mMDSC frequencies predict clinical benefit after therapy. A) Unsupervised cluster analysis of the expression of the indicated treatment-induced and pre-treatment myeloid and lymphoid markers. To identify clusters of correlated markers, hierarchical cluster analysis using TIGR software was performed, and average linkage analysis was done by Pearson correlation analysis. Values of the treatment-induced and pre-treatment parameters are given relative to the cut-off value (determined by Cox regression model as described in materials and methods); below cut-off in green and above cut-off in red. Kaplan Meier curves for B) group 2 (with high on-treatment cDC1/cDC3/monocyte activation and low pretreatment mMDSC frequencies: highlighted by white boxes in the heat plot) versus group 3 (with generally low on-treatment cDC1/cDC3/monocyte activation and high mMDSC frequencies) and C) group 1?+?2 (with high pre-treatment frequencies of CD4+CTLA4+ T cells: lower white box in heat plot) versus group 3. Statistical significance of the survival distribution was analyzed by log-rank testing and indicated with the given p-value. Number of patients and corresponding median survival for each group are given.

Back to article page